Evaluating the Safety and Pharmacokinetics of PC-1005 Administered Rectally to HIV-1 Seronegative Adults
Status:
Completed
Trial end date:
2019-04-19
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and pharmacokinetics of PC-1005 gel when
used as a rectal microbicide in HIV-uninfected men and women (cis or transgender) with a
history of consensual receptive anal intercourse.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)